Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by 180 Wealth Advisors LLC

180 Wealth Advisors LLC lessened its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 4.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,654 shares of the medical device company’s stock after selling 383 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Tandem Diabetes Care were worth $271,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in TNDM. Vanguard Group Inc. raised its stake in Tandem Diabetes Care by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company’s stock valued at $207,708,000 after purchasing an additional 18,571 shares during the last quarter. Eminence Capital LP raised its stake in Tandem Diabetes Care by 76.1% in the 3rd quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock valued at $114,028,000 after purchasing an additional 2,372,458 shares during the last quarter. Jennison Associates LLC raised its stake in Tandem Diabetes Care by 14.9% in the 4th quarter. Jennison Associates LLC now owns 1,290,590 shares of the medical device company’s stock valued at $38,176,000 after purchasing an additional 167,675 shares during the last quarter. GW&K Investment Management LLC acquired a new position in Tandem Diabetes Care in the 4th quarter valued at about $36,288,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in Tandem Diabetes Care by 0.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 793,488 shares of the medical device company’s stock valued at $16,481,000 after purchasing an additional 2,633 shares during the last quarter.

Analyst Upgrades and Downgrades

TNDM has been the subject of several analyst reports. Redburn Atlantic initiated coverage on shares of Tandem Diabetes Care in a research note on Thursday, May 30th. They issued a “buy” rating and a $60.00 target price for the company. Oppenheimer boosted their target price on shares of Tandem Diabetes Care from $47.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, June 10th. SVB Leerink raised shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $34.00 to $45.00 in a research note on Thursday, April 25th. Leerink Partnrs upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a report on Thursday, April 25th. Finally, StockNews.com upgraded Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Friday, April 19th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and an average price target of $51.25.

Insider Transactions at Tandem Diabetes Care

In other news, Director Dick Allen sold 5,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $51.68, for a total transaction of $258,400.00. Following the completion of the sale, the director now owns 24,396 shares in the company, valued at approximately $1,260,785.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Trading Down 0.3 %

Shares of NASDAQ:TNDM opened at $40.29 on Friday. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43. Tandem Diabetes Care, Inc. has a 1 year low of $13.82 and a 1 year high of $53.69. The stock has a 50-day simple moving average of $44.52 and a 200-day simple moving average of $33.84.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Thursday, May 2nd. The medical device company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.17. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. The business had revenue of $191.67 million during the quarter, compared to analysts’ expectations of $173.06 million. As a group, sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.71 EPS for the current year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.